COMPOSITIONS AND METHODS FOR PREDICTION OF CLINICAL OUTCOME FOR ALL STAGES AND ALL CELL TYPES OF NON-SMALL CELL LUNG CANCER IN MULTIPLE COUNTRIES

摘要

Lung cancer is one of the most commonly diagnosed cancers in the world. While numerous predictive genetic models of non-small cell lung cancer (NSCLC) have been proposed, but many current models fail to accurately predict patient survival when verified by other multiple datasets. Here, we successfully eliminated institutional variations and merged twelve datasets from different institutions to generate a training cohort of 1073 and a testing cohort of 659. From the training cohort, we identified 129 deferentially expressed probes or 95 genes (Table1-2) associated with Lung Cancer.;Here we showed that using seven genes from Table1-2 and combined these genes values with the clinical parameters of age and cancer stage to design the Lung Cancer Prognostic Index (LCPI). Using the LCPI, we were able to differentiate patient populations into low, intermediate, and high risk groups and predict patient survival probabilities for all stages and all cell types of NSCLC at 10 and 15 years. The overall survival probability of low risk group defined by LCPI at 15 years was 65%-100%. Those lung cancer patients were surgical curable. Any post-surgery treatment like ACT (adjuvant chemotherapy) might actually decrease survival probabilities or shorten the life of those patients.;We extensively verified the predictive ability of the LCPI model for overall survival and recurrence free survival using six datasets (n=1665) from five different countries, which included samples of multiple cancer stages and all cell types. Using this model, clinicians would be able to prevent thousands of NSCLC patients from receiving excessive and unnecessary treatments and ultimately prolong their lives.;This research has been published in the first issue of “EbioMedicine” (http://www.ebiomedicine.com/article/S2352-3964%2814%2900014-0/fulltext) which is a high quality peer review journal under editorial leadership of “Cell Press” and “The Lancet”.